Assessment of rosacea severity: A review of evaluation methods used in clinical trials - 17/06/15
, Steven R. Feldman, MD, PhD a, b, cAbstract |
Background |
Novel rosacea treatments are needed. Assessment methodologies for clinical trials of rosacea treatments are not standardized and are relatively inadequate. To determine the efficacy of new treatments, a valid and reliable assessment methodology is needed.
Objective |
We sought to determine the assessment methodologies used in clinical trials for rosacea treatments, to demonstrate the need for a valid and reliable assessment tool, and to describe the relevant properties of such a tool.
Methods |
PubMed and MEDLINE were searched for clinical trials of rosacea treatments since January 1, 1985.
Results |
In all, 32 clinical trials met inclusion criteria. Assessment methodologies were highly variable, and standardized assessment methodologies were used in only 3 studies. The various manifestations of rosacea were assessed inconsistently.
Limitations |
Eighteen articles could not be included as a result of lack of access to the full text.
Conclusions |
The diverse methodologies make the assessment of novel treatments and comparison of treatments difficult. A valid and reliable assessment tool is needed to properly assess novel treatments to improve the management of rosacea.
Le texte complet de cet article est disponible en PDF.Key words : erythema, ocular rosacea, papules and pustules, phymatous rosacea, rosacea, scale, self-assessment, severity, telangiectasias, treatment
Plan
| Center for Dermatology Research was supported in part by an unrestricted educational grant from Galderma Laboratories LP. |
|
| Disclosure: Dr Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, and Leo Pharma Inc. Dr Feldman has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel/GlaxoSmithKline, Celgene, and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Kikaku, Lilly, Merck & Co Inc, Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Qurient, Suncare Research, and Xenoport. He is on an advisory board for Pfizer Inc. Dr Feldman is the founder and holds stock in Causa Research and holds stock and is majority owner in Medical Quality Enhancement Corp. He receives Royalties from UpToDate and Xlibris. Mr Hopkinson, Dr Moradi Tuchayi, and Dr Alinia have no conflicts of interest to disclose. |
|
| Table II is available at www.jaad.org. |
Vol 73 - N° 1
P. 138 - juillet 2015 Retour au numéro
Article précédent
- High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review
- Cristián Navarrete-Dechent, Michael J. Veness, Nicolás Droppelmann, Pablo Uribe
- Angiogenesis and lymphangiogenesis in inflammatory skin disorders
- Gilda Varricchi, Francescopaolo Granata, Stefania Loffredo, Arturo Genovese, Gianni Marone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?